Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
Cellyan Biotechnology Co., Ltd (HKPD) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| SNYRQ Synergy CHC Corp. compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| HSIC Henry Schein, Inc. compare | 25.0× |
| CAH Cardinal Health, Inc. compare | 35.0× |
| HKPD Cellyan Biotechnology Co., Ltd | — |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)